Conditions: Chronic Kidney Disease Dialysis Hyperphosphatemia
Keywords: Chronic Kidney Disease Dialysis Hyperphosphatemia Phosphate binder
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 116
Healthy volunteers: no

Brief summary:
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia.

The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: MCI-196
Intervention descriptions: intervention 1: 3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose

Protocol document: